Gilead Sciences, Inc. (GILD) Friday announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy in patients with first-line metastatic triple-negative breast cancer (mTNBC).
The study met its primary goal showing statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line mTNBC
The safety profile of Trodelvy in the ASCENT-03 study was consistent with prior studies, and no new safety signals were identified.
Phase 3 studies of Trodelvy across HER2- breast cancer including the ASCENT-07 trial in patients with HR+/HER2- mBC who have received endocrine therapy, and the ASCENT-05 study in patients with early-stage TNBC (eTNBC) are underway. The drug is also being evaluated in additional phase 3 studies in various types of tumors, including lung and gynecologic cancers.
"Together with the recently announced positive results from the ASCENT-04 study evaluating Trodelvy plus Keytruda in patients with previously untreated PD-L1+ metastatic TNBC, Trodelvy now has the potential to be the backbone treatment for all patients across first-line mTNBC," the company said in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.